Post by account_disabled on Mar 11, 2024 4:32:11 GMT -5
Today's medicine is becoming more and more advanced; It has more technology and even better effects on the body, however, this is not entirely good since medicine is now being created that can cause addiction, such is the case of Purdue Pharma and its OxyContin.
Pharma can create a new drug empire
Purdue Pharma's addictive nature of the powerful painkilling opioid OxyContin could compete with the pharmaceutical giant in the next Pablo Escobar, according to testimony CNN obtained.
In a multidistrict litigation that took place France Mobile Number List in March, Richard Sackler was targeted for various aspects of the company's operation, from the marketing of the drug to his interaction with the sales team. Testimony showed that Sackler, who said his memory suffered from brain injuries stemming from a stroke, sometimes said he could not remember events.
Purdue Pharma Medicine
He defended the company by saying they did what was in their power at the time of marketing the drug.
Sackler received an email from his anesthesiologist friend, who said he had an acquaintance whose daughter was offered the drug at school in 2002.
Someone tried to sell him OxyContin in the hallways at school. I asked her what she knew about OxyContin. I never spoke of your company, etc., in her presence. Her response: 'It's a designer drug and kind of like heroin.' I hate to say this, but you could become the Pablo Escobar of the new millennium,” Sackler's friend wrote in an email, according to testimony first obtained by The Wall Street Journal.
For his part, Sackler's attorney, David Bernick, said in a statement that the testimony shows that Sackler made efforts to stop the abuse of OxyContin.
" As the full historical record becomes known, it is clear that Dr. Sackler supported Purdue's action plan to respond to growing evidence of widespread abuse and diversion of OxyContin," Bernick said.
Purdue Pharma Medicine
“That plan not only included cooperating with and following the guidance of public health authorities, but went further by voluntarily undertaking extensive efforts to prevent the abuse and diversion of prescription opioids.”
It is worth mentioning that Sackler was questioned about the testimony that is being used as discovery in part of the mass litigation in several districts where around 1,700 cases have been filed between different states and municipalities.
The initial lawsuit alleged that Purdue Pharma's owners, including Sackler, illegally directed hundreds of millions of dollars to other Sackler family properties and downplayed the addictive nature of opioids to doctors while pressuring sales representatives to to market their painkiller OxyContin.
Purdue Pharma alleges that the company transferred funds in order to threaten bankruptcy as a way to avoid paying restitution.
OxyContin is a long-acting version of oxycodone that is released over 12 hours. It was approved in 1995 by health authorities and was aggressively marketed by Purdue Pharma as a safer pain pill.
However, more than ten years ago the government filed charges for misleading doctors and the public about the addictive nature of the drug. The company and executives pleaded guilty and paid more than $600 million in fines.
Pharma can create a new drug empire
Purdue Pharma's addictive nature of the powerful painkilling opioid OxyContin could compete with the pharmaceutical giant in the next Pablo Escobar, according to testimony CNN obtained.
In a multidistrict litigation that took place France Mobile Number List in March, Richard Sackler was targeted for various aspects of the company's operation, from the marketing of the drug to his interaction with the sales team. Testimony showed that Sackler, who said his memory suffered from brain injuries stemming from a stroke, sometimes said he could not remember events.
Purdue Pharma Medicine
He defended the company by saying they did what was in their power at the time of marketing the drug.
Sackler received an email from his anesthesiologist friend, who said he had an acquaintance whose daughter was offered the drug at school in 2002.
Someone tried to sell him OxyContin in the hallways at school. I asked her what she knew about OxyContin. I never spoke of your company, etc., in her presence. Her response: 'It's a designer drug and kind of like heroin.' I hate to say this, but you could become the Pablo Escobar of the new millennium,” Sackler's friend wrote in an email, according to testimony first obtained by The Wall Street Journal.
For his part, Sackler's attorney, David Bernick, said in a statement that the testimony shows that Sackler made efforts to stop the abuse of OxyContin.
" As the full historical record becomes known, it is clear that Dr. Sackler supported Purdue's action plan to respond to growing evidence of widespread abuse and diversion of OxyContin," Bernick said.
Purdue Pharma Medicine
“That plan not only included cooperating with and following the guidance of public health authorities, but went further by voluntarily undertaking extensive efforts to prevent the abuse and diversion of prescription opioids.”
It is worth mentioning that Sackler was questioned about the testimony that is being used as discovery in part of the mass litigation in several districts where around 1,700 cases have been filed between different states and municipalities.
The initial lawsuit alleged that Purdue Pharma's owners, including Sackler, illegally directed hundreds of millions of dollars to other Sackler family properties and downplayed the addictive nature of opioids to doctors while pressuring sales representatives to to market their painkiller OxyContin.
Purdue Pharma alleges that the company transferred funds in order to threaten bankruptcy as a way to avoid paying restitution.
OxyContin is a long-acting version of oxycodone that is released over 12 hours. It was approved in 1995 by health authorities and was aggressively marketed by Purdue Pharma as a safer pain pill.
However, more than ten years ago the government filed charges for misleading doctors and the public about the addictive nature of the drug. The company and executives pleaded guilty and paid more than $600 million in fines.